Stravencon Launches Chinese Life Sciences Trade and Investment Initiative

The annual trade fair for Chinese pharmaceutical manufacturers,
CPhI China (www.cphi-china.com), which closed today after attracting
nearly 20,000 visitors from over 20 countries, was the scene for the
announcement of a new business initiative by Stravencon Ltd aiming to
bridge Chinese life science companies and the European and American
pharmaceutical markets. Stravencon Ltd. (www.stravencon.com) is a
London-based company with offices in New York and Shanghai dedicated
to fostering alliances among healthcare enterprises in Europe, the
United States and Asia. Stravencon founder and chief executive,
Douglas B. Andrews, described the new venture as follows:

"Chinese life science companies are the 'odd man out' of the
global healthcare market. Underappreciated by potential business
partners in Europe and the States, undervalued by prospective
investors and underrepresented in global equity markets, their time
has finally come. There is an enormous store of value within both the
Chinese industry and the Chinese healthcare market as such, waiting to
be released."

Mr. Andrews summarized the Stravencon Chinese healthcare
initiative as follows:

Providing a product trading platform among Chinese, European and
American healthcare concerns by:

-- Assisting Chinese enterprises to comply with regulatory
requirements in the EU and USA

-- Creating and coordinating marketing partnerships among
Chinese, European and American life science firms

-- Sourcing products from the EU and USA for marketing and
distribution in China

Identifying and mediating sources of finance in China, Europe and
the USA for Chinese life science companies

Supplying value-added services to Chinese life science
enterprises, such as:

-- Regulatory training

-- Corporate acquisitions

-- Executive recruitment in Europe and North America

Stravencon Ltd. is the first company to provide all three forms of
business collaboration to Chinese life science enterprises as well as
European and American firms interested in penetrating the fast-growing
Chinese market.

China will soon be the world's fourth largest market for
healthcare products. Its prescription pharmaceutical market is
expected to grow to GBP 12 billion by 2010.